Avatrombopag approved in the EU for the treatment of primary chronic immune thrombocytopenia (ITP)

Avatrombopag has been approved for use in adults refractory to other treatments (e.g. corticosteroids, immunoglobulins). It is currently approved in the UK for the treatment of severe thrombocytopenia in adults with liver disease scheduled to undergo an invasive procedure.

Source:

Biospace Inc.